| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 55.4 | 39.8 | 14.0 |
| Other income | 1.0 | 1.0 | 0.9 |
| Total income | 56.4 | 40.8 | 14.9 |
| Profit before exceptional items & tax | 1.9 | -1.3 | -0.4 |
| Profit before tax | 1.9 | -1.3 | -0.4 |
| Net profit | 1.4 | -0.8 | -0.3 |
| Operating margin | 3.4% | -3.2% | -2.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +295.70% |
|---|
BSE results filing, NSE: ADIRASA. Figures extracted from the filing.
Genpharmasec Ltd: key numbers
- Share price
- ₹1.15
- Market cap
- ₹63.68 Cr
- Revenue (annual)
- ₹139.9 Cr
- Net profit (annual)
- ₹1.60 Cr
- P/E (TTM)
- -522.7×Sector 50.4×
- Promoter holding
- 29.98%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genpharmasec Ltd
All →Genpharmasec Annual Report
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.
Genpharmasec Management Change
Genpharmasec Limited has re-appointed Sohan Chaturvedi as Executive Director for a 36-month term effective April 26, 2027. This change is approved by the Board.
Genpharmasec Annual General Meeting
Genpharmasec Limited has announced the closure of its share transfer books from September 23 to 29, 2026, for the 34th Annual General Meeting.
Genpharmasec Board Meeting Outcome
Genpharmasec Limited announced the schedule for its 34th Annual General Meeting and approved the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director.
Genpharmasec Promoter Buying: ₹0.71 Cr
Promoter and Director Rajesh Sadhwani acquired 65,00,000 equity shares via market purchase. This increases his stake from 14.09% to 15.26% in Genpharmasec Ltd.
- Value
- ₹0.71 Cr
- Promoter stake change
- +1.17%
Genpharmasec Q1 FY27 Results: Net Loss of ₹0.2 Cr
Genpharmasec Ltd reported revenue from operations of ₹49.7 Cr (+314.2% YoY) and a net loss of ₹0.2 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.2 Cr